Толерантность и минимизация иммуносупрессивной терапии после трансплантации печени

В обзоре современных публикаций рассматриваются молекулярные механизмы толерантности печени и ее аллотрансплантатов в аспекте минимизации и возможностей отмены иммуносупрессивной терапии, главным образом, в отдаленном периоде после трансплантации печени. Представлены сведения о клинических испытаниях Treg с целью индукции толерантности. Продемонстрированы данные нового консенсусного исследования об индивидуализации режимов иммуносупрессивной терапии. Рассматриваются варианты возможной отмены иммуносупрессии как в ранние, так и в отдаленные сроки после ТП. Предлагается к исследованию путь изучения лимфопролиферативного потенциала реципиента трансплантата печени, поскольку не только отторжением определяется продолжительность жизни, но и степенью влияния иммуносупрессии на костный мозг в зависимости от возраста пациента.

1. Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015; 61 (2): 668–677. doi: 10.1002/hep.27538.

2. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM et al. Induction of immunological tolerance by porcine liver allografts. Nature. 1969; 223 (5205): 472–476. doi: 10.1038/223472a0. PMID: 4894426.

3. Ronca V, Wootton G, Milani C, Cain O. The Immunological basis of liver allograft rejection. Front Immunol. 2020; 11: 2155. doi: 10.3389/fimmu.2020.02155. PMID: 32983177.

4. Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy. 2016; 18: 160–171. doi: 10.1016/j.jcyt.2015.10.011.

5. Taner T, Abrol N, Park WD, Hansen MJ, Gustafson MP, Lerman LO et al. Phenotypic transcriptional, and functional analysis of liver mesenchymal stromal cells and their immunomodulatory properties. Liver Transpl. 2020; 26: 549–563. doi: 10.1002/lt.25718.

6. Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today. 1999; 20: 27–32. doi: 10.1016/S0167-5699(98)01378-4.

7. Thomson AW, Humar A, Lakkis FG, Metes DM. Regulatory dendritic cells for promotion of liver transplant operational tolerance: rationale for a clinical trial and accompanying mechanistic studies. Hum Immunol. 2018; 79: 314–321. doi: 10.1016/j.humimm.2017.10.017.

8. Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7- homolog 1-dependent CD8+ T cell tolerance. Hepatology. 2008; 47: 296–305. doi: 10.1002/hep.21965.

9. Shalev I, Selzner N, Shyu W, Grant D, Levy G. Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl. 2012; 18: 761–770. doi: 10.1002/lt.23458.

10. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008; 14: 88–92. doi: 10.1038/nm1688.

11. Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016; 64: 632–643. doi: 10.1002/hep.28459.

12. Landwehr-Kenzel S, Issa F, Luu SH, Schmuck M, Lei H, Zobel A et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am J Transplant. 2014; 14: 594–606. doi: 10.1111/ajt.12629.

13. Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020; 395: 1627–1639. doi: 10.1016/S0140-6736(20)30167-7.

14. MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016; 126: 1413–1424. doi: 10.1172/JCI 82771.

15. Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MA, Hannen RF, Cooper D et al. Expression of a chimeric antigen receptor specific for donor HLA Class I enhances the potency of human regulatory T Cells in preventing human skin transplant rejection. Am J Transplant. 2017; 17: 931–943. doi: 10.1111/ajt.14185.

16. Whitehouse GP, Hope A, Sanchez-Fueyo A. Regulatory T-cell therapy in liver transplantation. Transpl Int. 2017; 30 (8): 776–784. doi: 10.1111/tri.12998. PMID: 28608637.

17. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004; 39 (2): 273–278. PMID: MEDLINE:14767974.

18. Lim EJ, Chin R, Nachbur U, Silke J, Jia Z, Angus PW et al. Effect of immunosuppressive agents on hepatocyte apoptosis post-liver transplantation. PLoS ONE. 2015; 10 (9): e0138522. doi: 10.1371/journal.pone.0138522.

19. Johnson JD, Ao Z, Ao P, Li H, Dai L-J, He Z et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 2009; 18 (8): 833–845. PMID: MEDLINE:19500470. doi: 10.3727/096368909X471198.

20. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol. 2006; 45 (6): 786–796. PMID: MEDLINE:17050028.

21. De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol. 2017; 31 (2): 199–209. doi: 10.1016/j.bpg.2017.03.001. PMID: 28624108.

22. Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F et al. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 2020; 14 (6): 930–943. doi: 10.1007/s12072-020-10091-5. PMID: 33099753.

23. Shevchenko OP, Kurabekova RM, Tsiroulnikova OM. Biomarkers of immune tolerance in liver transplantation. Russian Journal of Transplantology and Artificial Organs. 2016; 18 (3): 137–144. doi.org/10.15825/1995-1191-2016-3-137-144.

24. Zhang CX, Wen PH, Sun YL. Withdrawal of immunosuppression in liver transplantation and the mechanism of tolerance. Hepatobiliary Pancreat Dis Int. 2015; 14 (5): 470–476. doi: 10.1016/s1499-3872(15)60411-8. PMID: 26459722.

25. Shaked A, DesMarais MR, Kopetskie H, Feng S, Punch JD, Levitsky J et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant. 2019; 19 (5): 1397– 1409. doi: 10.1111/ajt.15205.

26. Benítez C, Londoño MC, Miquel R, Manzia TM, Abraldes JG, Lozano JJ et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013; 58 (5): 1824–1835. doi: 10.1002/hep.26426. PMID: 23532679.

27. Shoutko AN, Gerasimova OA, Ekimova LP, Zherebtsov FK, Mus VF, Matyurin KS et al. Lymphocyte reproductive activity normalized to numbers of hematopoietic stem cells in blood and rate of death in fatal diseases. Int J of Genetics and Genomics. 2017; 5: 54–62. doi: 10.11648/j.ijgg.20170505.12.